| Primary information |
|---|
| OV_ID | OV_46 |
| Virus Name | Adenovirus |
| Strain | Ad-cycE |
| Virus type | DNA |
| Virus family | Adenoviridae |
| Modification in virus genome | E1b-deleted mutant with a human cyclin E promoter driving an intact E1A expression cassette |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | No |
| Source of cell line | NA |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | Female FVB/NCr mice isograft for 5× 10^6 ED-1 murine lung cancer cell lines |
| In-vivo virus concentration | 1.5 × 10^9 IFU (on 0, 2, 4 and 6 days) |
| In-vivo toxicity | NA |
| In-vivo result | Reduction in tumor volume to 52 cubic millimeter compared to control 150 cubic millimeter after 36 days |
| Mode of delivery | Intratumorally |
| Pathway induction | NA |
| Immunogenic effect | Activates CDK2 and targets the transcriptional repressor pRb |
| Clinical trial | NA |
| PMID | 26475304 |